Cost-Effectiveness of Treatments for Moderate-to-Severe Psoriasis at Chonburi Hospital
Keywords:
Psoriasis, Cost-effectiveness, Conventional systemic therapy, Biologic therapy, PhototherapyAbstract
Background: Psoriasis is a chronic inflammatory skin disease that significantly impairs quality of life and imposes a substantial economic burden. Various treatment modalities are currently available; however, real-world cost-effectiveness data from Thai public hospitals remain limited. This study aimed to compare the monthly cost and cost-effectiveness of conventional systemic therapy, phototherapy and biologic therapy for moderate-to-severe psoriasis.
Methods: This retrospective descriptive study was conducted among patients with moderate-to-severe psoriasis treated between October 2024 and October 2025. Pateints were categorized into three treatment groups: conventional therapy ,phototherapy and biologic therapy. Data on medication costs, topical medication costs, laboratory monitoring costs, and total monthly expenditures were analysed and compared with treatment effectiveness
Results: The biologic group demonstrated the lowest median PASI score (2.9) and the highest effectiveness rate (100%), but also the highest median total monthly cost (13,918.5 THB/month). This group incurred the lowest topical medication costs (median 994.5 THB/month). Conventional systemic therapy had the lowest total monthly cost (4,583 THB/month) and the greatest overall cost-effectiveness (7,892.8 THB per responder). However, among conventional systemic agents, cyclosporine showed a cost per responder closer to biologic therapy than to other oral treatments. No patients in the phototherapy group achieved the effectiveness criteria during the study period.
Conclusion: Biologic therapy provides the highest clinical effectiveness but required substantially higher costs, whereas conventional systemic therapy remains the most cost-effective option overall. Notably, cyclosporine demonstrated a cost per responder closer to biologic therapy, indicating that its use may warrant careful consideration, particularly for long-term treatment.
Keywords: Psoriasis, Cost-effectiveness, Conventional systemic therapy, Biologic therapy, Phototherapy
References
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19;323(19):1945–60. Doi:10.1001/jama.2020.4006
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.
Vañó-Galván S, Sánchez-Regaña M, Garcia-Domínguez M, Carretero G, de la Cueva P, Fernández-Redondo V, et al. Cost-effectiveness of home-based phototherapy vs biological drugs for moderate-to-severe psoriasis. Actas Dermosifiliogr. 2012;103(2):127–35.
Azizam NA, Ismail A, Sulong S, Nor NM. Cost-effectiveness analysis of psoriasis treatment modalities in Malaysia. Int J Health Policy Manag. 2019;8(7):394–402. Doi:10.15171/ijhpm.2019.17
Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. JAMA Dermatol. 2010;146(1):46–54. Doi:10.1001/archdermatol.2009.316
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Region 3 Medical and Public Health Journal - วารสารวิชาการแพทย์และสาธารณสุข เขตสุขภาพที่ 3
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
